ABSTRACT
The aim of the present study was to evaluate the efficacy and tolerability of the dopamine agonist drug dihydroergocryptine in the suppression of puerperal lactation. A single blind and placebo-controlled study was performed. A total of 90 postpartum women was acutely or repeatedly treated with dihydroergocryptine at different doses in order to investigate the efficacy of this drug in the suppression of puerperal lactation and to find the optimum dose for therapy. Prolactin levels, mammary symptomatology and rebound effects were monitored during the repeated treatment and also 1 and 8 days after drug discontinuation. With acute administration, dihydroergocryptine significantly reduced prolactin levels only at the dose of 10 mg and not at 5 mg. With repeated administration, a daily dose of 15 mg was more effective than 10 mg in reducing prolactin levels and in suppressing puerperal lactation. No side-effects occurred during the treatment. These results suggest that dihydroergocryptine might be considered an effective drug in the suppression of puerperal lactation.
Subject(s)
Dihydroergotoxine/pharmacology , Lactation/drug effects , Postpartum Period/drug effects , Prolactin/blood , Administration, Oral , Adult , Dihydroergotoxine/administration & dosage , Dose-Response Relationship, Drug , Female , Humans , Lactation/blood , Radioimmunoassay , Single-Blind MethodABSTRACT
In double-blind conditions, ST-679 (a single oral 1200 mg dose in 20 patients), or paracetamol (a single oral dose of 1000 mg in 20 patients) was administered to forty patients who presented pain as a result of obstetrical-gynecological surgery. The study proposed to evaluate the analgesic efficacy and tolerability of ST-679, a new non-steroid antiphlogistic drug, as compared to a reference drug amply utilized in clinical practice such as paracetamol. The average estimation of tolerability, with regard to paracetamol, was significantly in favor of ST-679.
Subject(s)
Acetaminophen/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Genital Diseases, Female/surgery , Glycine/analogs & derivatives , Pain, Postoperative/drug therapy , Pregnancy Complications/surgery , Pyrroles/therapeutic use , Administration, Oral , Adolescent , Adult , Aged , Double-Blind Method , Drug Tolerance , Female , Glycine/therapeutic use , Humans , Middle Aged , Pain Measurement , PregnancyABSTRACT
Ibopamine, a peripheral dopamine agonist, was administered to 80 postpartum women to assess its effect on prolactin (PRL) and milk production. The acute administration of 400 mg significantly decreased serum PRL for more than 240 min. Women given ibopamine 400 mg t.d.s. for 5 to 10 days showed suppression of PRL and milk letdown was prevented in the latter group. No side effects were observed on repeated administration. Ibopamine may be a useful alternative to other dopaminergic compounds for the inhibition of puerperal lactation.
Subject(s)
Deoxyepinephrine/analogs & derivatives , Diuretics/pharmacology , Lactation/drug effects , Prolactin/blood , Adult , Deoxyepinephrine/administration & dosage , Deoxyepinephrine/pharmacology , Diuretics/administration & dosage , Female , HumansABSTRACT
In the present study, 122 post puerperal women received at random bromoergocriptine, domperidone, bromoergocriptine plus domperidone or placebo treatment. Domperidone started 20-24 h after delivery and given for 10 or 15 days did not antagonize either the decrease in serum PRL induced by bromoergocriptine or the inhibition of lactation. It did suppress nausea and vomiting in the patients. The results are compatible with the idea that domperidone binds with a higher affinity than bromoergocriptine to DA (dopamine) receptors in the area postrema or the stomach. The converse phenomenon occurs at the level of the DA receptors on the PRL- secreting cells of the anterior pituitary gland.
